The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage.

The rectal carriage of glycopeptide-resistant Enterococcus spp. (GRE) had been established at approximately 50% in a series of prevalence studies on a busy haematological malignancy unit. The aim of this study was to reduce the chance of patients acquiring GRE. A prospective three-phase sequential study was performed. In Phase 1, the acquisition rate of GRE detectable by rectal swab was measured without any intervention for a period of 4 months. For the following 8 months (Phase 2), the first-line treatment for febrile neutropenic episodes was changed from monotherapy with ceftazidime to piperacillin/tazobactam. In addition, an intense education programme was introduced to improve hygiene to reduce the risk of case-to-case spread. In the final 4 months (Phase 3), ceftazidime was again used as the first-line antimicrobial, while continuing the same level of training in relation to hygiene. The carriage of GRE was measured from rectal swabs done weekly. During the initial 4 months, at any time, 40-50% of patients in the unit were colonized with GRE, and 43 of 75 (57%) new patients initially negative for GRE acquired it within 6 weeks of their admission. In Phase 2, 25 patients out of 129 (19%) acquired GRE, with the acquisition rate falling progressively so that in the last 3 months, only one new patient acquired GRE (logrank comparison of probabilities for cohort 1 vs cohort 2b: P < 0.0001). A return to ceftazidime in Phase 3 was associated with a return of the risk of acquiring detectable GRE colonization, despite continued hygiene teaching and surveillance, with 21 out of 58 patients (36%) acquiring GRE (cohort 1 vs cohort 3: P = 0.08). Glycopeptide usage was not reduced during the period of the study. Clinical cases were seen only in Phases 1 and 3. Although the reduction in the risk of acquiring GRE may have been due in part to hygiene practices as well as to the change in antimicrobial usage, or may have occurred spontaneously for other reasons, the return of the problem with the reintroduction of ceftazidime strongly suggests that this antibiotic was responsible for encouraging the acquisition of detectable GRE.

[1]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[2]  D. Landman,et al.  Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Starr,et al.  Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime , 1995, BMJ.

[4]  J. Morris,et al.  Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin: Establishment of Endemicity in a University Medical Center , 1995, Annals of Internal Medicine.

[5]  D. Dunn,et al.  Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Gilchrist,et al.  Recommendations for Preventing the Spread of Vancomycin Resistance , 1995, Infection Control &#x0026; Hospital Epidemiology.

[7]  Elaine Larson,et al.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  J. Mcgowan,et al.  Do Intensive Hospital Antibiotic Control Programs Prevent the Spread of Antibiotic Resistance? , 1994, Infection Control &#x0026; Hospital Epidemiology.

[9]  T. Frieden,et al.  Emergence of vancomycin-resistant enterococci in New York City , 1993, The Lancet.

[10]  K. Singh,et al.  Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  G. Woods,et al.  Hospital-acquired Infection with Vancomycin-resistant Enterococcus faecium Transmitted by Electronic Thermometers , 1992, Annals of Internal Medicine.

[12]  R. Gaynes,et al.  A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. , 1992 .

[13]  R. Gaynes,et al.  Major trends in the microbial etiology of nosocomial infection. , 1991, The American journal of medicine.

[14]  N. Woodford,et al.  High-level vancomycin-resistant enterococci causing hospital infections , 1989, Epidemiology and Infection.

[15]  J. Duval,et al.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. , 1988, The New England journal of medicine.

[16]  L. Bougueleret,et al.  High-level, plasmid-borne resistance to gentamicin in Streptococcus faecalis subsp. zymogenes , 1979, Antimicrobial Agents and Chemotherapy.

[17]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.